Newly and relapsed epithelial ovarian carcinoma: ESMO Clinical Recommendations for diagnosis, treatment and follow-up

被引：44

作者：

Aebi, S. ^{[1
,2
]}

Castiglione, M. ^{[3
]}

机构：

[1] Univ Bern, Inselspital, Breast Gynecol Canc Ctr, CH-3010 Bern, Switzerland

[2] Univ Bern, Inselspital, Dept Med Oncol, CH-3010 Bern, Switzerland

[3] Univ Geneva, Inst Social & Prevent Med, Geneva, Switzerland

来源：

ANNALS OF ONCOLOGY | 2009年 / 20卷

关键词：

GYNECOLOGIC-ONCOLOGY-GROUP; PHASE-III TRIAL; PLUS CARBOPLATIN; INTERGROUP TRIAL; RANDOMIZED-TRIAL; STAGE-III; CANCER; PACLITAXEL; CHEMOTHERAPY; CISPLATIN;

D O I：

10.1093/annonc/mdp117

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

[No abstract available]

引用

页码：21 / 23

页数：3

共 22 条

[1] Intraperitoneal cisplatin and paclitaxel in ovarian cancer [J].

Armstrong, DK ;

Bundy, B ;

Wenzel, L ;

Huang, HQ ;

Baergen, R ;

Lele, S ;

Copeland, LJ ;

Walker, JL ;

Burger, RA .

NEW ENGLAND JOURNAL OF MEDICINE, 2006, 354 (01) :34-43

[2] Randomized phase III trial of three versus six cycles of adjuvant carboplatin and paclitaxel in early stage epithelial ovarian carcinoma: A Gynecologic Oncology Group study [J].

Bell, Jeffrey ;

Brady, Mark F. ;

Young, Robert C. ;

Lage, Janice ;

Walker, Joan L. ;

Look, Katherine Y. ;

Rose, G. Scott ;

Spirtos, Nick M. .

GYNECOLOGIC ONCOLOGY, 2006, 102 (03) :432-439

[3] Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: A meta-analysis [J].

Bristow, RE ;

Tomacruz, RS ;

Armstrong, DK ;

Trimble, EL ;

Montz, FJ .

JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (05) :1248-1259

[4] Delaying the primary surgical effort for advanced ovarian cancer: A systematic review of neoadjuvant chemotherapy and interval cytoreduction [J].

Bristow, Robert E. ;

Eisenhauer, Eric L. ;

Santillan, Antonio ;

Chi, Dennis S. .

GYNECOLOGIC ONCOLOGY, 2007, 104 (02) :480-490

[5] A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer [J].

du Bois, A ;

Lück, HJ ;

Meier, W ;

Adams, HP ;

Möbus, V ;

Costa, S ;

Bauknecht, T ;

Richter, B ;

Warm, M ;

Schröder, W ;

Olbricht, S ;

Nitz, U ;

Jackisch, C ;

Emons, G ;

Wagner, U ;

Kuhn, W ;

Pfisterer, J .

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2003, 95 (17) :1320-1330

[6] Role of surgery in ovarian carcinoma [J].

Fader, Amanda Nickles ;

Rose, Peter G. .

JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (20) :2873-2883

[7] Management of asymptornatic patients on follow-up for ovarian cancer with rising CA-125 concentrations [J].

Goonewardene, Tyronne I. ;

Hall, Marcia R. ;

Rustin, Gordon J. S. .

LANCET ONCOLOGY, 2007, 8 (09) :813-821

[8] Long-term survival advantage for women treated with pegylated liposomal doxorubicin compared with topotecan in a phase 3 randomized study of recurrent and refractory epithelial ovarian cancer [J].

Gordon, AN ;

Tonda, M ;

Sun, S ;

Rackoff, W .

GYNECOLOGIC ONCOLOGY, 2004, 95 (01) :1-8

[9]

KAVANAGH JJ, 2000, STAGING CLASSIFICATI, P95

[10] Phase III randomized trial of 12 versus 3 months of maintenance paclitaxel in patients with advanced ovarian cancer after complete response to platinum and paclitaxel-based chemotherapy: A Southwest Oncology Group and Gynecologic Oncology Group trial [J].

Markman, M ;

Liu, PY ;

Wilczynski, S ;

Monk, B ;

Copeland, LJ ;

Alvarez, RD ;

Jiang, C ;

Alberts, D .

JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (13) :2460-2465

← 1 2 3 →